Korean J Hematol 2010; 45(4):
Published online December 31, 2010
https://doi.org/10.5045/kjh.2010.45.4.247
© The Korean Society of Hematology
1Department of Pediatrics, College of Medicine, Hanyang University Hospital, Seoul, Korea.
2Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
3Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Ulsan College of Medicine & Asan Medical Center, Seoul, Korea.
4Department of Medical Genetics, College of Medicine, Hanyang University, Seoul, Korea.
Correspondence to : Correspondence to Jong Jin Seo, M.D. Division of Pediatrics Hematology/Oncology, Department of Pediatrics, University of Ulsan College of Medicine & Asan Medical Center, 388-1, Pungnap 2-dong, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3383, Fax: +82-2-473-3725, jjseo@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
It has been hypothesized that genetic alteration at the cellular level may have a significant effect on cellular mechanisms controlling the proliferation and apoptosis of Langerhans cells (LCs).
We examined whether p16 protein expression can be used to predict the outcome of Langerhans cell histiocytosis (LCH). Archival paraffin blocks from children diagnosed with LCH and followed at the Asan Medical Center and Chungnam National University Hospital between March 1998 and February 2008 were studied.
Slides were stained with p16 antibody and evaluated semi-quantitatively using the following scale: negative, no staining; ±, weakly positive; 1+, staining similar to lymphocytes surrounding the LCs; 2+, stronger staining than lymphocytes; 3+, much stronger staining than lymphocytes. Negative and ± groups were assigned to a lower expression group (LEG) and the 1+, 2+, and 3+ groups were assigned to a higher expression group (HEG). The median age of the 51 patients (24 girls, 27 boys) was 49 (range, 0.6-178) months, and LCH was diagnosed based on CD1a positivity. p16 protein was expressed to varying degrees in all but one specimen. There was a greater tendency toward multisystem disease, risk organ involvement, and relapse in the HEG than in the LEG.
The p16 protein may have a significant effect on cellular mechanisms controlling the proliferation and apoptosis of LCs, and thus may influence the clinical outcome and prognosis of LCH.
Keywords Genes, p16, Histiocytosis, Langerhans cells, Immunohistochemistry
Korean J Hematol 2010; 45(4): 247-252
Published online December 31, 2010 https://doi.org/10.5045/kjh.2010.45.4.247
Copyright © The Korean Society of Hematology.
Sun-Young Kim1, Hyoung-Jin Kim1, Hee-Jin Kim2, Mee-Rim Park3, Kyung-Nam Koh3, Ho-Joon Im3, Chul-Hoon Lee4, and Jong-Jin Seo3*
1Department of Pediatrics, College of Medicine, Hanyang University Hospital, Seoul, Korea.
2Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
3Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Ulsan College of Medicine & Asan Medical Center, Seoul, Korea.
4Department of Medical Genetics, College of Medicine, Hanyang University, Seoul, Korea.
Correspondence to: Correspondence to Jong Jin Seo, M.D. Division of Pediatrics Hematology/Oncology, Department of Pediatrics, University of Ulsan College of Medicine & Asan Medical Center, 388-1, Pungnap 2-dong, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3383, Fax: +82-2-473-3725, jjseo@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
It has been hypothesized that genetic alteration at the cellular level may have a significant effect on cellular mechanisms controlling the proliferation and apoptosis of Langerhans cells (LCs).
We examined whether p16 protein expression can be used to predict the outcome of Langerhans cell histiocytosis (LCH). Archival paraffin blocks from children diagnosed with LCH and followed at the Asan Medical Center and Chungnam National University Hospital between March 1998 and February 2008 were studied.
Slides were stained with p16 antibody and evaluated semi-quantitatively using the following scale: negative, no staining; ±, weakly positive; 1+, staining similar to lymphocytes surrounding the LCs; 2+, stronger staining than lymphocytes; 3+, much stronger staining than lymphocytes. Negative and ± groups were assigned to a lower expression group (LEG) and the 1+, 2+, and 3+ groups were assigned to a higher expression group (HEG). The median age of the 51 patients (24 girls, 27 boys) was 49 (range, 0.6-178) months, and LCH was diagnosed based on CD1a positivity. p16 protein was expressed to varying degrees in all but one specimen. There was a greater tendency toward multisystem disease, risk organ involvement, and relapse in the HEG than in the LEG.
The p16 protein may have a significant effect on cellular mechanisms controlling the proliferation and apoptosis of LCs, and thus may influence the clinical outcome and prognosis of LCH.
Keywords: Genes, p16, Histiocytosis, Langerhans cells, Immunohistochemistry
Light micrographs of LCH lesions after immunohistochemical staining (×400). Scattered morphologically positive LCs are shown. A semi-quantitative evaluation was made using the following grading system: negative, no staining; ±, weakly positive
Six-year event-free survival (EFS) rate according to immunohistochemical grade. The probability of 6-year EFS for LEG patients was 92.9±6.9%, whereas that for HEG patients was 70.3±8.1%. The difference was not significant according to the log-rank test.
Table 1 . Clinical manifestations according to the immunohistochemical grade..
Abbreviations: LEG, lower expression group; HEG, higher expression group..
Table 2 . Organ involvement according to the immunohistochemical grade..
Abbreviations: LEG, lower expression group; HEG, higher expression group..
Jong-Jin Seo, Taeshik Cho, Sun-Young Kim, Ibrahim Nassour, Hee-Jin Kim, Yeon-Jung Lim, Kyung-Nam Koh, and Ho-Joon Im
Korean J Hematol 2012; 47(4): 267-272Won-ik Choi, You Cheol Jeong, Sun Young Kim, So Dam Kim, John Paul Pribis, Hee-Jin Kim, Kyung-Nam Koh, Ho-Joon Im, Young-Ho Lee, and Jong-Jin Seo
Korean J Hematol 2011; 46(3): 186-191Taegeun Lee, Chan-Jeoung Park, Miyoung Kim, Young-Uk Cho, Seongsoo Jang, Sang-Hyun Hwang, Jung-Hee Lee, Dok Hyun Yoon
Blood Res 2023; 58(1): 71-76
Light micrographs of LCH lesions after immunohistochemical staining (×400). Scattered morphologically positive LCs are shown. A semi-quantitative evaluation was made using the following grading system: negative, no staining; ±, weakly positive
Six-year event-free survival (EFS) rate according to immunohistochemical grade. The probability of 6-year EFS for LEG patients was 92.9±6.9%, whereas that for HEG patients was 70.3±8.1%. The difference was not significant according to the log-rank test.